Published in PLoS Negl Trop Dis on June 08, 2010
Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs (2012) 1.24
Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis (2011) 1.17
Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS Negl Trop Dis (2014) 1.00
Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. PLoS One (2014) 0.90
Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh. PLoS Negl Trop Dis (2015) 0.89
Visceral leishmaniasis outbreak in South Sudan 2009-2012: epidemiological assessment and impact of a multisectoral response. PLoS Negl Trop Dis (2014) 0.87
Association of pro-inflammatory cytokines and iron regulatory protein 2 (IRP2) with Leishmania burden in canine visceral leishmaniasis. PLoS One (2013) 0.83
Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions. Front Immunol (2016) 0.76
Epidemiological Feature of Visceral Leishmaniasis in China, 2004-2012. Iran J Public Health (2015) 0.75
Permutation tests for joinpoint regression with applications to cancer rates. Stat Med (2000) 24.62
Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ (2007) 17.85
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Prevalence of HIV infection in conflict-affected and displaced people in seven sub-Saharan African countries: a systematic review. Lancet (2007) 3.77
A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ (2006) 3.11
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis (2006) 2.29
Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis (2004) 2.29
Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med (1996) 2.10
Leishmaniasis in Sudan. Visceral leishmaniasis. Trans R Soc Trop Med Hyg (2001) 2.00
Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg (2006) 1.91
Unseen Kala-azar deaths in south Sudan (1999-2002). Trop Med Int Health (2006) 1.83
Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology (1977) 1.68
Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis (2008) 1.66
Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol (2006) 1.55
Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg (1990) 1.51
Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop Med Int Health (2003) 1.41
Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol (2004) 1.32
A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol (2002) 1.32
Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis (1993) 1.29
Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg (2007) 1.28
Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) (1988) 1.27
Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop Med Int Health (2003) 1.26
Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, north-eastern Kenya, and south-eastern Ethiopia in 2000-01. Trans R Soc Trop Med Hyg (2004) 1.19
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg (2000) 1.15
Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann Trop Med Parasitol (1998) 0.99
A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother (2006) 0.99
Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev Soc Bras Med Trop (2003) 0.93
Pathophysiology of visceral leishmaniasis - some recent concepts. Indian J Med Res (2006) 0.89
High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet (2011) 4.73
A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med (2007) 4.07
Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis (2005) 3.35
IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol (2007) 2.75
Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest (2007) 2.38
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis (2006) 2.29
Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis (2004) 2.29
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis (2005) 2.07
Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci U S A (2012) 2.05
Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg (2006) 1.91
Evaluation of a mass distribution programme for fine-mesh impregnated bednets against visceral leishmaniasis in eastern Sudan. Trop Med Int Health (2007) 1.89
Unseen Kala-azar deaths in south Sudan (1999-2002). Trop Med Int Health (2006) 1.83
Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg (2006) 1.72
Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am J Trop Med Hyg (2003) 1.72
Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis (2008) 1.66
Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am J Trop Med Hyg (2009) 1.58
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
Comparison of bronchoscopy and gastric washings in the investigation of smear-negative pulmonary tuberculosis. Clin Infect Dis (2003) 1.53
Treating HIV/AIDS and leishmaniasis coinfection in Ethiopia. CMAJ (2005) 1.45
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis (2012) 1.41
Ethnic variation in inflammatory profile in tuberculosis. PLoS Pathog (2013) 1.39
Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis (2011) 1.38
Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis (2007) 1.36
1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection. Immunology (2008) 1.33
Human African trypanosomiasis in areas without surveillance. Emerg Infect Dis (2010) 1.30
Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg (2007) 1.28
Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop Med Int Health (2003) 1.26
Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs (2012) 1.24
Developments in the treatment of visceral leishmaniasis. Expert Opin Emerg Drugs (2009) 1.23
Etiology and management of genitourinary tuberculosis. Nat Rev Urol (2011) 1.23
Malaria in the Nuba Mountains of Sudan: baseline genotypic resistance and efficacy of the artesunate plus sulfadoxine-pyrimethamine and artesunate plus amodiaquine combinations. Trans R Soc Trop Med Hyg (2005) 1.22
Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PLoS One (2008) 1.19
Paromomycin. Trans R Soc Trop Med Hyg (2008) 1.11
Preventing diarrhoea with household ceramic water filters: assessment of a pilot project in Bolivia. Int J Environ Health Res (2006) 1.03
Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev (2009) 1.02
A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan. J Antimicrob Chemother (2006) 0.99
High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. Antimicrob Agents Chemother (2010) 0.96
Efficient Ex vivo stimulation of Mycobacterium tuberculosis-specific T cells by genetically detoxified Bordetella pertussis adenylate cyclase antigen toxoids. Infect Immun (2005) 0.95
Diagnosis and treatment strategies of tuberculous intestinal perforations: a case series. Eur J Gastroenterol Hepatol (2012) 0.92
Treatment options for visceral leishmaniasis. Expert Rev Anti Infect Ther (2006) 0.92
The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes Control (2010) 0.91
Depression in paediatric chronic fatigue syndrome. Arch Dis Child (2013) 0.91
Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre. Pathog Glob Health (2012) 0.91
Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia. Am J Trop Med Hyg (2011) 0.90
Concomitant malaria among visceral leishmaniasis in-patients from Gedarif and Sennar States, Sudan: a retrospective case-control study. BMC Public Health (2013) 0.90
First case of typical Old World cutaneous leishmaniasis treated with miltefosine. Int J Dermatol (2007) 0.88
Leishmania major promastigotes inhibit dendritic cell motility in vitro. Infect Immun (2002) 0.87
Outbreak of West Nile virus causing severe neurological involvement in children, Nuba Mountains, Sudan, 2002. Trop Med Int Health (2004) 0.87
The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers? Int J Mol Epidemiol Genet (2011) 0.82
Utility of lymph node aspiration in the diagnosis of visceral leishmaniasis in Sudan. Am J Trop Med Hyg (2007) 0.81
Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: an exhaustive cross-sectional survey. PLoS Negl Trop Dis (2012) 0.80
What stops children with a chronic illness accessing health care: a mixed methods study in children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). BMC Health Serv Res (2011) 0.79
Assessing the Association between Thermotolerant Coliforms in Drinking Water and Diarrhea: An Analysis of Individual-Level Data from Multiple Studies. Environ Health Perspect (2016) 0.78
Breastfeeding practices among the Old Order Mennonites in Ontario, Canada: a multiple methods study. J Hum Lact (2013) 0.78
Leaf concentrate as an alternative to iron and folic acid supplements for anaemic adolescent girls: a randomised controlled trial in India. Public Health Nutr (2009) 0.77
Extra-pulmonary tuberculosis developing at sites of previous trauma. J Infect (2012) 0.77
Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int J Dermatol (2004) 0.76